Ryan Livingston

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Articles

Among currently approved oral JAKis, deuruxolitinib 8 mg BID appeared in the analysis to provide the greatest short-term efficacy for those living with severe disease. | Image Credit: onephoto - stock.adobe.com

Deuruxolitinib Shows Greatest Short-Term Efficacy Among JAKis for Severe Alopecia Areata

October 30th 2025

Deuruxolitinib 8 mg BID was found to be the most effective oral JAK inhibitor for severe alopecia areata in a new meta-analysis.

PAH | Image Credit: Maggie-sora.chatgpt.com

FDA Reviewing Sotatercept-csrk Label Expansion for PAH

July 14th 2025

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777